1. Direct screening for chromatin status on DNA barcodes in yeast delineates the regulome of H3K79 methylation by Dot1.
- Author
-
Vlaming H, Molenaar TM, van Welsem T, Poramba-Liyanage DW, Smith DE, Velds A, Hoekman L, Korthout T, Hendriks S, Altelaar AFM, and van Leeuwen F
- Subjects
- Chromatin Immunoprecipitation, DNA, Fungal chemistry, DNA, Fungal genetics, Genetic Testing, Genetics, Microbial methods, Methylation, Molecular Biology methods, Sequence Analysis, DNA, Chromatin chemistry, DNA, Fungal metabolism, Gene Expression Regulation, Fungal, Histone-Lysine N-Methyltransferase metabolism, Histones metabolism, Nuclear Proteins metabolism, Protein Processing, Post-Translational, Saccharomyces cerevisiae genetics, Saccharomyces cerevisiae Proteins metabolism
- Abstract
Given the frequent misregulation of chromatin in cancer, it is important to understand the cellular mechanisms that regulate chromatin structure. However, systematic screening for epigenetic regulators is challenging and often relies on laborious assays or indirect reporter read-outs. Here we describe a strategy, Epi-ID, to directly assess chromatin status in thousands of mutants. In Epi-ID, chromatin status on DNA barcodes is interrogated by chromatin immunoprecipitation followed by deep sequencing, allowing for quantitative comparison of many mutants in parallel. Screening of a barcoded yeast knock-out collection for regulators of histone H3K79 methylation by Dot1 identified all known regulators as well as novel players and processes. These include histone deposition, homologous recombination, and adenosine kinase, which influences the methionine cycle. Gcn5, the acetyltransferase within the SAGA complex, was found to regulate histone methylation and H2B ubiquitination. The concept of Epi-ID is widely applicable and can be readily applied to other chromatin features., Competing Interests: FvL: The Netherlands Cancer Institute and FvL are entitled to royalties that may result from licensing the yeast H2BK123ub-specific monocloncal antibody according to IP policies of the Netherlands Cancer Institute. The other authors declare that no competing interests exist.
- Published
- 2016
- Full Text
- View/download PDF